Postischemic administration of basic fibroblast growth factor improves sensorimotor function and reduces infarct size following permanent focal cerebral ischemia in the rat

Experimental Neurology

Volumn 177, Issue 2, 2002, Pages 531-537

  Li, Qiu ^a   Stephenson, Diane ^a  

^a PFIZER INC   (United States)

Author keywords

bFGF; Infarction; Middle cerebral artery occlusion; Rotarod; Stroke; Trophic factors

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; DRUG VEHICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG EFFICACY; FUNCTIONAL ASSESSMENT; LATENT PERIOD; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOTOR DYSFUNCTION; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; RAT; SENSORIMOTOR FUNCTION; SENSORY DYSFUNCTION; TASK PERFORMANCE;

EID: 0036433581     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2002.7994     Document Type: Article

References (32)

1. Baird, A. 1994. Fibroblast growth factors: Activities and significance of non-neurotrophin neurotrophic growth factors. Curr. Opin. Neurobiol. 4: 78-86.
2. Ballinger, M. D., V. Shyamala, L. D. Forrest, et al. 1999. Semi-rational design of a potent, artifical agonist of fibroblast growth factor receptors. Nature Biotechnol. 17: 1199-1204.
3. Belluardo, N., M. Blum, and G. Mudo. 1998. Acute intermittent nicotine treatment produces regional increases of basic fibroblast growth factor messenger RNA and protein in the tel- and diencephalon of the rat. Neuroscience 83: 723-740.
4. Belluardo, N., G. Mudo, G. Caniglia, Q. Cheng, M. Blum, and K. Fuxe. 1999. The nicotinic acetylcholine receptor agonist ABT-594 increases FGF-2 expression in various rat brain regions. Neuroreport 10: 3909-3913.
5. Bogousslavsky, J., and G. Donnan, et al. 2000. Fibroblast (trafermin) in acute stroke: Results of the European-Australian phase 2/3 safety and efficacy trial. Cerebrovasc. Dis. 10(S2): 106.
6. De Keyser, J., G. Sulter, and P. G. Luiten. 1999. Clinical trials with neuroprotective drugs in acute ischaemic stroke: Are we doing the right thing? Trends Neurosci. 22: 535-540.
7. Fisher, M., M-E. Meadows, T. Do, J. Weise, V. Trubetskoy, M. Chaarette, and S. P. Finklestein. 1995. Delayed treatment with intravenous basic fibroblast growth factor reduces infarct size following permanent focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 15: 953-959.
8. Fisher, M. (Ed.). Stroke Therapy. 2001. 2nd Ed. Butterworth Heinemann.
9. Finklestein, S. P. Brain ischemia: Basic concepts and clinical relevance. In Growth Factors in Stroke (Caplan, Ed.), pp. 37-41. Springer-Verlag, London.
10. Hamm, R. J., B. R. Pike, D. M. O'Dell, B. G. Lyeth, and L. W. Jenkins. 1994. The rotarod test: An evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. J. Neurotrauma 11: 187-196.
11. Hunter, A. J., K. B. Mackay, and D. C. Rogers. 1998. To what extent have functional studies of ischaemia in animals been useful in the assessment of potential neuroprotective agents? Trends Pharmacol. Sci. 19: 59-66.
12. Jiang, N., S. Finklestein, and T. Do. 1996. Delayed intravenous administration of basic fibroblast growth factor (bFGF) reduces infarct volume in a model of focal cerebral ischemia/reperfusion in the rat. J. Neurol. Sci. 139: 173-179.
13. Kawamata, T., N. E. Alexis, W. D. Dietrich, and S. P. Finklestein. 1996. Intracisternal basic fibroblast growth factor enhances behavioral recovery following focal cerebral infarction in the rat. J. Cereb. Blood Flow Metab. 16: 542-547.
14. Kawamata, T., W. D. Dietrich, T. Schallert, J. E. Gotts, R. R. Cocke, L. I. Benowitz, and S. P. Finklestein. 1997. Intracisternal basic fibroblast growth factor enhances functional recovery and up-regulates the experssion of a molecular marker of neuronal sprouting following focal cerebral infarction. Proc. Natl. Acad. Sci. USA 94: 8179-8184.
15. Kawamata, T., J. Ren, J.-H. Cha, and S. P. Finklestein. 1999. Intracisternal antisense oligonucleotide to growth associated protein-43 blocks the recovery-promoting effects of basic fibroblast growth factor after focal stroke. Exp. Neurol. 158: 89-96.
16. Kitagawa, H., C. Sasaki, K. Sakai, A. Mori, Y. Mitsumoto, T. Mori, Y. Fukuchi, Y. Setoguchi, and K. Abe. 1999. Adenovirus-mediated gene transfer of glial cell line-derived neurotrophic factor prevents ischemic brain injury after transient middle cerebral artery occlusion in rats. J. Cereb. Blood Flow Metab. 19: 1336-1344.
17. Koketsu, N., D. J. Berlove, M. A. Moskowitz, N. W. Kowall, C. G. Caday, and S. P. Finklestein. 1994. Pretreatment with intraventricular basic fibroblast growth factor decreases infarct size following focal cerebral ischemia in rats. Ann. Neurol. 35: 451-457.
18. Ramirez, J. J., S. P. Finklestein, J. Keller, W. Abrams, M. N. George, and T. Parakh. 1999. Basic fibroblast growth factor enhances axonal sprouting after cortical injury in rats. Neuroreport 10: 1201-1204.
19. Regli, L., R. E. Anderson, and F. B. Meyer. 1994. Basic fibroblast growth factor increases cortical blood flow in vivo. Brain Res. 665: 155-157.
20. Ren, J. M., and S. P. Finklestein. 1997. Time window of infarct reduction by intravenous basic fibroblast growth factor in focal cerebral ischemia. Eur. J. Pharmacol. 327: 11-16.
21. Rosenblatt, S., K. Irikura, C. G. Caday, S. P. Finklestein, and M. A. Moskowitz. 1994. Basic fibroblast growth factor (bFGF) dilates rat pial arterioles. J. Cereb. Blood Flow Metab. 14: 70-74.
22. Rogers, D. C., C. A. Campbell, and J. L. Stretton. 1997. Correlation between motor impairment and infarct volume after permanent and transient middle cerebral artery occlusion in the rat. Stroke 28: 2060-2066.
23. Rozas, G., M. J. Guerra, and J. L. Labandeira-Garcia. 1997. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res. Protocols 2: 75-84.
24. Schabitz, W. R., F. Li, K. Irie, B. W. Sandage, K. W. Locke, and M. Fisher. 1999. Synergistic effects of a combination of low-dose basic fibroblast growth factor and citicoline after temporary experimental focal ischemia. Stroke 427-431.
25. Stroemer, R. P., T. A. Kent, and C. E. Hulsebosch. 1995. Neocortical neural sprouting, synaptogenesis, and behavioral recovery after neocortical infarction in rats. Stroke 26: 2134-2144.
26. Stroke Therapy Academic Industry Roundtable (STAIR). 1999. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30: 2752-2758.
27. Stroke Therapy Academic Industry Roundtable (STAIR II). 2001. Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 32: 1598-1606.
28. Van der Staay, F. J. 2000. The Study of Behavioral Dysfunctions: An Evaluation of Selected Animal Models. BCN, The Netherlands.
29. Walicke, P. A. 1988. Basic and acidic fibroblast growth factors have trophic effects on neurons from multiple CNS regions. J. Neurosci. 8: 2618-2627.
30. Wanaka, A., E. M. Johnson, and J. Milbrandt. 1990. Localization of bFGF receptor mRNA in the adult rat central nervous system by in situ hybridization. Neuron 5: 267-281.
31. Yamashita, K., C. Wiessner, D. Lindholdm, H. Thoenen, and K. A. Hossmann. 1997. Post-occlusion treatment with BDNF reduces infarct size in a model of permanent occlusion of the middle artery in rat. Met. Brain Dis. 12: 271-280.
32. Zhang, L., J. Chen, Y. Li, Z. G. Zhang, and M. Chopp. 2000. Quantitative measurement of motor and somatosensory impairments after mild (30 min) and severe (2 h) transient middle cerebral artery occlusion in rats. J. Neurol. Sci. 174: 141-146.